Treatment of Bile Acid Diarrhea With Glucagon-Like Peptide 1 Receptor Agonists: A Promising Yet Understudied Approach.

IF 3 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Clinical and Translational Gastroenterology Pub Date : 2025-01-14 DOI:10.14309/ctg.0000000000000815

Anne-Marie Ellegaard, Martin L Kårhus, Matilde Winther-Jensen, Asger B Lund, Filip K Knop

引用次数: 0

Abstract

Bile acid diarrhea (BAD) is a chronic and socially debilitating disease characterized by abdominal pain, diarrhea, urgency, and fecal incontinence. Recently, in a 6-week randomized controlled trial, we showed that the glucagon-like peptide 1 receptor agonist (GLP-1RA) liraglutide is superior to bile acid sequestration (considered standard-of-care) using colesevelam in reducing BAD symptoms. The emergence of new, more potent, and longer-acting GLP-1RAs has spurred an interest in these treatments in BAD management. Here, we review the literature on different GLP-1RAs in BAD treatment and outline their potential mode of actions, highlight knowledge gaps, and outline the need for further clinical evidence generation.

查看原文本刊更多论文

GLP-1受体激动剂治疗胆汁酸性腹泻：一种有希望但研究不足的方法。

摘要：胆汁酸性腹泻（BAD）是一种以腹痛、腹泻、急症和大便失禁为特征的慢性社会衰弱性疾病。最近，在一项为期六周的随机对照试验（RCT）中，我们发现胰高血糖素样肽1受体激动剂（GLP-1RA）利拉鲁肽在减轻BAD症状方面优于使用colesvelam的胆汁酸隔离（被认为是标准治疗）。新的、更有效的、更长效的GLP-1RAs的出现激发了人们对这些治疗BAD的兴趣。在这里，我们回顾了关于不同GLP-1RAs在BAD治疗中的文献，概述了它们潜在的作用模式，强调了知识空白，并概述了进一步临床证据生成的需求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

7.00

自引率

0.00%

发文量

114

审稿时长

16 weeks

期刊介绍： Clinical and Translational Gastroenterology (CTG), published on behalf of the American College of Gastroenterology (ACG), is a peer-reviewed open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology. CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. CTG also welcomes hypothesis-generating small studies, methods papers, and translational research with clear applications to human physiology or disease. Colon and small bowel Endoscopy and novel diagnostics Esophagus Functional GI disorders Immunology of the GI tract Microbiology of the GI tract Inflammatory bowel disease Pancreas and biliary tract Liver Pathology Pediatrics Preventative medicine Nutrition/obesity Stomach.